Nodality Launches PathPro™ Product Line Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R D

Business News
Print
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., which is focused on solving drug development challenges, announced today the launch of its PathPro™ product line. PathPro products leverage the unique capabilities of Nodality’s proprietary Single Cell Network Profiling (SCNP) technology, offering predefined multiparametric flow cytometry-based experimental panels. These panels allow us to study customer inhibitor activity and identify disease subgroups and differential responses in

imageimage
image

Read more